Bayesian Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Bayesian Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-740	Closed	-$9.6K	–	960
2023 Q4	$9.6K	Buy	+740	New	+$9.97K	﹤0.01%	701
2023 Q2	–	Sell	-792	Closed	-$46.2K	–	941
2023 Q1	$46.2K	Sell	792 -2,117	-73%	-$105K	0.01%	716
2022 Q4	$148K	Buy	+2,909	New	+$202K	0.02%	632
2021 Q2	–	Sell	-1,800	Closed	-$284K	–	533
2021 Q1	$284K	Buy	+1,800	New	+$379K	0.07%	360
2020 Q2	–	Sell	-937	Closed	-$270K	–	657
2020 Q1	$270K	Buy	+937	New	+$258K	0.06%	495
2019 Q4	–	Sell	-673	Closed	-$97K	–	677
2019 Q3	$97K	Buy	+673	New	+$91.2K	0.02%	478

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bayesian Capital Management's KPTI Position: Q1 2024 in Review

Bayesian Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q1 2024, closing a stake of 740 shares — an estimated $9.6K sold.

Bayesian Capital Management first reported a position in KPTI in Q3 2019 and held it in 6 quarters. The position peaked at $284K in Q1 2021. 113 funds tracked by Wall St. Rank hold KPTI as of Q1 2024.

Bayesian Capital Management reported no remaining Karyopharm Therapeutics position as of Q1 2024 after selling out during the quarter.
Bayesian Capital Management sold 740 Karyopharm Therapeutics shares in Q1 2024, an estimated $9.6K.
Bayesian Capital Management first reported a position in Karyopharm Therapeutics in Q3 2019 and held it in 6 quarters.
Bayesian Capital Management's Karyopharm Therapeutics position peaked at $284K in Q1 2021.
113 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2024.

Based on Bayesian Capital Management's 13F filing for Q1 2024, filed 15 May 2024.